Characteristics of study population and H1N1/09 vaccine responses
| . | HCs (n = 17) . | HIV+ (n = 25) . | H1N1/09-vaccinated subjects . | |||
|---|---|---|---|---|---|---|
| HCs (n = 8) . | HIV+ R (n = 8) . | HIV+ NR (n = 8) . | HIV+ (R vs NR) . | |||
| Age, y | 36 ± 13.5 | 43.7 ± 13.7 | 40 ± 13.5 | 46.9 ± 8.6 | 43.7 ± 15.1 | NS |
| CD4 T cells, cells/mm3 | NA | 574 ± 345 | NA | 687 ± 463 | 607 ± 309 | NS |
| CD8 T cells, cells/mm3 | NA | 777 ± 321 | NA | 717 ± 280 | 813 ± 424 | NS |
| B cells, % | 16.8 ± 3.4 | 14.5 ± 4.4 | 18.7 ± 2.8 | 12.3 ± 5.3 | 16.6 ± 4.2 | NS |
| Viral load, HIV RNA copies/mL | NA | 57.7 (< 40-369) | NA | < 40 | 163 ± 178 (< 40-369) | NS |
| H1N1 Ab titer | ||||||
| Before vaccination (T0) | NA | NA | < 20 | < 20 | < 20 | NS |
| At 4 weeks (T2) | NA | NA (80-20 480) | 720 (80-2560) | 480 | < 20 | P = .04 |
| . | HCs (n = 17) . | HIV+ (n = 25) . | H1N1/09-vaccinated subjects . | |||
|---|---|---|---|---|---|---|
| HCs (n = 8) . | HIV+ R (n = 8) . | HIV+ NR (n = 8) . | HIV+ (R vs NR) . | |||
| Age, y | 36 ± 13.5 | 43.7 ± 13.7 | 40 ± 13.5 | 46.9 ± 8.6 | 43.7 ± 15.1 | NS |
| CD4 T cells, cells/mm3 | NA | 574 ± 345 | NA | 687 ± 463 | 607 ± 309 | NS |
| CD8 T cells, cells/mm3 | NA | 777 ± 321 | NA | 717 ± 280 | 813 ± 424 | NS |
| B cells, % | 16.8 ± 3.4 | 14.5 ± 4.4 | 18.7 ± 2.8 | 12.3 ± 5.3 | 16.6 ± 4.2 | NS |
| Viral load, HIV RNA copies/mL | NA | 57.7 (< 40-369) | NA | < 40 | 163 ± 178 (< 40-369) | NS |
| H1N1 Ab titer | ||||||
| Before vaccination (T0) | NA | NA | < 20 | < 20 | < 20 | NS |
| At 4 weeks (T2) | NA | NA (80-20 480) | 720 (80-2560) | 480 | < 20 | P = .04 |
HIV-infected patients with undetectable viral load (< 40 copies/mL) were scored as 40 copies/mL for calculation of mean plasma virus load. H1N1 Ab titer was measured prevaccination (T0) and 4 weeks after vaccination (T2). Differences between HIV-infected vaccine responders versus nonresponders were analyzed by Student t test.
R indicates vaccine responders; NR, vaccine nonresponders; NA, not available; and NS, not significant.